R.E.C.K vs Exparel for Pain After Robotic Kidney Surgery
This study compares two pain management approaches, R.E.C.K (a mix of ropivacaine, epinephrine, clonidine, and ketorolac) and Exparel, for people having robotic surgery to remove part or all of a kidney (nephrectomy) due to kidney cancer. Researchers want to see which treatment is better at controlling pain after surgery, how much pain medicine you need, and how long you stay in the hospital. The main goal is to measure your pain levels using a Numeric Rating Scale (NRS) for seven days after surgery. You may be able to join if you are 18 or older and are scheduled for this type of surgery. The study is currently recruiting participants.
- Study design
- This is a randomized study, meaning participants will be assigned by chance to receive either R.E.C.K or Exparel. The study plans to enroll 170 participants.
- What's involved
- You will receive the study treatment during your surgery. After discharge, you will record your pain levels and any pain medications you take in a diary.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your pain levels will be monitored for seven days (168 hours) after surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
R.E.C.K vs Exparel in Robotic Nephrectomy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Roy Ornob, MD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) pain intensity scores through 7 days (168 hours) for participants receiving Exparel vs. R.E.C.K.Day of Surgery to Day 7 Post-Surgery
Assess pain intensity (evaluated by NRS) after surgery on the as response to the prompt: "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain are you having right now?" The AUC will be derived for each participant from self-reported pain scores and will be summarized by treatment group. Generalized linear models with main effect of treatment will be estimated to test for significant differences in AUC between the arms.